Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Marketable Securities

Marketable Securities

3 Months Ended

Mar. 31, 2012

3.	Marketable Securities

Cost and fair value of the Company's marketable securities are as follows:

	Cost		Gross Unrealized		Fair
Securities available-for-sale	Basis		Gains/Losses		Value
March 31, 2012:
State and municipal obligations	$	1,950,000	$	-	$	1,950,000

December 31, 2011:
State and municipal obligations	$	1,950,000	$	-	$	1,950,000

Amortized cost and fair value at March 31, 2012 by contractual maturity are shown below. Expected maturities will differ from contractual maturities because the Company may redeem certain securities at par.

	Cost		Fair
Maturity	Basis		Value
10 years or more	$	1,950,000	$	1,950,000

- Definition

Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.

+ References + Details